

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 December 2024 (19.12.2024)



(10) International Publication Number
WO 2024/256618 A1

(51) International Patent Classification:

C07D 403/04 (2006.01) A61P 25/28 (2006.01)
A61P 25/00 (2006.01) A61K 31/437 (2006.01)

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2024/066517

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

14 June 2024 (14.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2023/066306

16 June 2023 (16.06.2023) EP

(71) Applicant: **VIVORYON THERAPEUTICS N.V.**
[DE/DE]; Weinbergweg 22, 06120 Halle (Saale) (DE).

(72) Inventor; and

(71) Applicant: **HEISER, Ulrich** [DE/DE]; Kirschbergweg 28,
06120 Halle (Saale) (DE).

(74) Agent: **MAIKOWSKI & NINNEMANN PATENTAN-
WÄLTE PARTNERSCHAFT MBB**; Postfach 15 09 20,
10671 Berlin (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLU-
TAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT

(57) Abstract: The present invention is concerned with a crystalline pharmaceutically acceptable salt of the glutaminy cyclase in-
hibitor Varoglutamstat. Varoglutamstat is chemically designated as (S)-1- (1H-benzo[d]imidazol-5-yl)-5-(4-propoxyphenyl)imidazo-
lidin-2-one and is also known under the code PQ912. The invention further relates to a polymorphic form of the hydrochloride salt of (S)-
1-(1H-benzo[d]imidazol-5-yl)-5-(4-propoxyphenyl)imidazolidin-2-one, to processes for preparing said hydrochloride salt and its poly-
morphic form, pharmaceutical compositions containing the same, therapeutic uses thereof and methods of treatment employing them.



WO 2024/256618 A1